STAT5 contributes to antiapoptosis in melanoma

Melanoma Research

Volumn 18, Issue 6, 2008, Pages 378-385

  Hassel, Jessica C ^a,b   Winnemöller, Dirk ^a   Schartl, Manfred ^a   Wellbrock, Claudia ^a,c  

^a UNIVERSITY OF WÜRZBURG   (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

^c UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

Apoptosis; bcl X; Melanoma; Signal transducers and activators of transcription 5; Signal transduction

Indexed keywords

MUSCARINIC RECEPTOR KINASE; PHOSPHOTRANSFERASE; PROTEIN BCL XL; STAT1 PROTEIN; STAT5 PROTEIN; UNCLASSIFIED DRUG;

ANIMAL CELL; APOPTOSIS; ARTICLE; CELL ACTIVATION; CELL NUCLEUS; CELL PROLIFERATION; CELL SURVIVAL; CONTROLLED STUDY; CORRELATION ANALYSIS; ENZYME ACTIVATION; GENE TARGETING; HUMAN; HUMAN CELL; MELANOCYTE; MELANOMA; MOUSE; NONHUMAN; PIGMENT CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN TRANSPORT; SIGNAL TRANSDUCTION; UPREGULATION;

EID: 56849116334     PISSN: 09608931     EISSN: None     Source Type: Journal    
DOI: 10.1097/CMR.0b013e32830ce7d7     Document Type: Article

References (41)

1. Wellbrock C, Fischer P, Schartl M. Receptor tyrosine kinase Xmrk mediates proliferation in Xiphophorus melanoma cells. Int J Cancer 1998; 76:437-442.
2. Wittbrodt J, Lammers R, Malitschek B, Mäueler W, Raulf F, Telling A, et al. Novel putative receptor tyrosine kinase encoded by the melanoma-inducing Tu locus in Xiphophorus. Nature 1989; 341:415-421.
3. Morcinek JC, Weisser C, Geissinger E, Schartl M, Wellbrock C. Activation of STAT5 triggers proliferation and contributes to anti-apoptotic signalling mediated by the oncogenic Xmrk kinase. Oncogene 2002; 21:1668-1678.
4. Calo V, Migliavacca M, Bazan V, Macaluso M, Buscemi M, Gebbia N, et al. STAT proteins: from normal control of cellular events to tumorigenesis. J Cell Phys 2003; 197:157-168.
5. Bowman T, Garcia R, Turkson J, Jove R. STATs in oncogenesis. Oncogene 2000; 19:2474-2488.
6. Baudler M, Schartl M, Altschmied J. Specific activation of a STAT family member in Xiphophorus melanoma cells. Exp Cell Res 1999; 249:212-220.
7. Wellbrock C, Geissinger E, Gomez A, Fischer P, Friedrich K, Schartl M. Signalling by the oncogenic receptor tyrosine kinase Xmrk leads to activation of STAT5 in Xiphophorus melanoma. Oncogene 1998; 16:3047-3056.
8. Florenes VA, Lu C, Bhattacharya N, Rak J, Sheehan C, Slingerland JM, et al. Interleukin-6 dependent induction of the cyclin dependent kinase inhibitor p21WAF1/CIP1 is lost during progression of human malignant melanoma. Oncogene 1999; 18:1023-1032.
9. Kortylewski M, Heinrich PC, Mackiewicz A, Schniertshauer U, Klingmüller U, Nakajima K, et al. Interleukin-6 and oncostatin M-induces growth inhibiton of human A375 melanoma cells is STAT-dependent and involves upregulation of the cyclin-dependent kinase inhibitor p27/Kip1. Oncogene 1999; 18:3742-3753.
10. Ransohoff RM. Cellular responses to interferons and other cytokines: the JAK-STAT paradigm. N Engl J Med 1998; 338:616-618.
11. Kortylewski M, Komyod W, Kauffmann M, Bosserhoff A, Heinrich PC, Behrmann I. Interferon-gamma-mediated growth regulation of melanoma cells: involvement of STAT1-dependent and STAT1-independent signals. J Invest Dermatol 2004; 122:414-422.
12. Jaster R, Tschirch E, Bittorf T, Brock J. Role of STAT5 in interferon-alpha signal transduction in Ba/F3 cells. Cell Signal 1999; 11:331-335.
13. Su L, David M. Distinct mechanisms of STAT phosphorylation via the interferon-alpha/beta receptor. Selective inhibition of STAT3 and STAT5 by piceatannol. J Biol Chem 2000; 275:12661-12666.
14. Levy DE, Gilliland DG. Divergent roles of STAT1 and STAT5 in malignancy as revealed by gene disruptions in mice. Oncogene 2000; 19:2505-2510.
15. Wellbrock C, Weisser C, Hassel JC, Fischer P, Becker J, Vetter CS, et al. STAT5 contributes to interferon resistance of melanoma cells. Curr Biol 2005; 15:1629-1639.
16. Socolovsky M, Fallon AE, Wang S, Grugnara C, Lodish HF. Fetal anemia and apoptosis of red cell progenitors in STAT5a-/-5b-/- mice: a direct role for Stat5 in Bcl-X(L) induction. Cell 1999; 98:181-191.
17. Leiter U, Schmid RM, Kaskel P, Peter RU, Krahn G. Antiapoptotic bcl-2 and bcl-xL in advanced malignant melanoma. Arch Dermatol Res 2000; 292:225-223.
18. Fendly BM, Winget M, Hudziak RM, Lipari MT, Napier MA, Ullrich A. Characterization of murine monoclonal antibodies reactive to either the human epidermal growth factor receptor or HER2/neu gene product. Cancer Res 1990; 50:1550-1558.
19. Zhong Z, Wen Z, Darnell JE. Stat3: a STAT family member activated by tyrosine phosphorylation in response to EGF and IL-6. Science 1994; 264:95-98.
20. Grillot DA, Gonzalez-Garcia N, Ekhterae D, Duan L, Inohara N, Ohta S, et al. Genomic organization, promoter region analysis, and chromosome localization of the mouse bcl-x gene. J. Immunol 1997; 158:4750-4757.
21. Moriggl R, Gouilleux-Gruart V, Jahne R, Berchtold S, Gartmann C, Liu X, et al. Deletion of the carboxyl-terminal transactivation domain of MGF-Stat5 results in sustained DNA binding and a dominant negative phenotype. Mol Cell Biol 1996; 16:5691-5700.
22. Winkler C, Wittbrodt J, Lammers R, Ullrich A, Schartl M. Ligand-dependent tumor induction in medakafish embryos by a Xmrk receptor tyrosine kinase transgene. Oncogene 1994; 9:1517-1525.
23. Wittbrodt J, Lammers R, Malitschek B, Ullrich A, Schartl M. The Xmrk receptor tyrosine kinase is activated in Xiphophorus malignant melanoma. EMBO J 1992; 11:4239-4246.
24. Wellbrock C, Weisser C, Geissinger E, Troppmair J, Schartl M. Activation of p59(Fyn) leads to melanocyte dedifferentiation by influencing MKP-1-regulated mitogen-activated protein kinase signaling. J Biol Chem 2002; 277:6443-6454.
25. Lockshin A, Giovanella BC, De Ipolyi PD, Williams LJ, Mendoza JT, Yim SO, et al. Exceptional lethality for nude mice of cells derived from a primary human melanoma. Cancer Res 1985; 45:345-350.
26. Cornil J, Theodorescu D, Man S, Herly M, Jambrosic J, Kerbel RS. Fibroblast cell interactions with human melanoma cells affect tumor cell growth as a function of tumor progression. Proc Natl Acad Sci USA 1991; 88:6028-6032.
27. Wong LH, Krauer KG, Hatzinisiriou I, Estcourt MJ, Hersey P, Tam ND, et al. Interferon-resistant human melanoma cells are deficient in ISGF3 components, STAT1, STAT2, and p48-ISGF3gamma. J Biol Chem 1997; 272:28779-28785.
28. Pansky A, Hildebrand P, Fasler-Kan E, Baselgia L, Ketterer S, Beglinger C, et al. Defective Jak-STAT signal transduction pathway in melanoma cells resistant to growth inhibition by interferon-alpha. Int J Cancer 2000; 85:720-725.
29. Onishi M, Nosaka T, Misawa K, Mui AL, Gorman D, McMahon M, et al. Identification and characterization of a constitutively active STAT5 mutant that promotes cell proliferation. Mol Cell Biol 1998; 18:3871-3879.
30. Lu C, Rak JW, Kobayashi H, Kerbel RS. Increased resistance to oncostatin M-induced growth inhibition of human melanoma cell lines derived from advanced-stage lesions. Cancer Res 1993; 53:2708-2711.
31. Auguste P, Guillet C, Fourcin M, Olivier C, Veziers J, Puplard-Barthelaix A, et al. Signalling of type II oncostatin M receptor. J Biol Chem 1997; 272:15760-15764.
32. Asao H, Fu XY. Interferon-gamma has dual potentials in inhibiting or promoting cell proliferation. J Biol Chem 2000; 275:867-874.
33. Lazar-Molnar E, Hegyesi H, Toth S, Falus A. Autocrine and paracrine regulation by cytokines and growth factors in melanoma. Cytokine 2000; 12:547-554.
34. Mirmohammadsadegh A, Hassan M, Bardenheuer W, Marini A, Gustrau A, Mambiar S, et al. STAT5 phosphorylation in malignant melanoma is important for survival and is mediated through SRC and JAK1 kinases. J Invest Dermatol 2006; 126:2272-2280.
35. Tang L, Tron VA, Reed JC, Mah KJ, Krajewska M, Li G, et al. Expression of apoptosis regulators in cutaneous malignant melanoma. Clin Cancer Res 1998; 4:1865-1871.
36. Arita Y, Santiago-Schwarz F, Coppock DL. Survival mechanisms induced by 12-O-tetradecanoyl-13-acetate in normal human melanocytes include inhibiton of apoptosis and increased Bcl-2 expression. Melanoma Res 2000; 10:412-420.
37. Gross A, Pilcher K, Blachly-Dyson E, Basso E, Jockel J, Bassik MC, et al. Biochemical and genetic analysis of the mitochondrial response of yeast to BAX and BCL-X(L). Mol Cell Biol 2000; 20:3125-3136.
38. Liu R, Liu CB, Mohi MG, Arai K, Watanabe S. Analysis of mechanisms involved in the prevention of gamma irradiation- induced apoptosis by hGM-CSF. Oncogene 2000; 19:571-579.
39. Heere-Ress E, Thallinger C, Lucas T, Schlagbauer-Wadl H, Wacheck V, Monia BP, et al. Bcl-X(L) is a chemoresistance factor in human melanoma cells that can be inhibitied by antisense therapy. Int J Cancer 2002; 99:29-34.
40. Olie RA, Hafner C, Kuttel R, Sigrist B, Willers J, Dummer R, et al. Bcl-2 and bcl-xL antisense oligonucleotides induce apoptosis in melanoma cells of different clinical stages. J Invest Dermatol 2002; 118:505-512.
41. Shirogane T, Fukada T, Muller JMM, Shima DT, Hibi M, Hirano T. Synergistic roles for pim-1 and c-myc in STAT3-mediated cell cycle progression and antiapoptosis. Immunity 1999; 11:709-719.